This article is part of the supplement: Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma
Review
Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma
-
* Corresponding author: Alicia M Mohr mohr@umdnj.edu
1 Assistant Professor of Surgery, Department of Surgery, New Jersey Medical School, Newark, New Jersey, USA
2 COL, MC, US Army, Chief, Trauma Division, Trauma Consultant for The Surgeon General Commander, US Army Institute of Surgical Research, Fort Sam Houston, Texas, USA
3 Associate Professor of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland, USA
4 Professor, Departement d'Anesthesie-Reanimation, Hopital de Bicetre, Le Kremlin-Bicetre, France
Critical Care 2005, 9(Suppl 5):S37-S42 doi:10.1186/cc3784
Published: 7 October 2005Abstract
In this article we describe the current use of recombinant activated factor VII (rFVIIa; NovoSeven®) in trauma patients. Emphasis is placed on current uses as defined by key studies, efficacy data, and safety data. Most published studies in trauma patients are retrospective case studies and reports, although an international, double-blind, randomized, controlled, phase II study has been conducted that reported on the efficacy of rFVIIa in reducing the amount of blood products transfused in blunt trauma patients. That study demonstrated the efficacy and safety profile of this hemostatic agent as compared with placebo as adjunctive therapy in the management of severe bleeding associated with trauma. Further prospective, randomized, and placebo-controlled clinical trials will yield more information on the role of rFVIIa in the management of traumatic bleeding.